In IPF, patients treated with IFN-γ for 12 months exhibited reduced CXCL5 levels in BAL [242,275], suggesting that CXCL5 activity may be a critical angiogenic factor in IPF [242,273,275]. This evidence concerns the gene CXCL5 and idiopathic pulmonary fibrosis.